Literature DB >> 1469394

The dopaminergic response in multiple system atrophy.

A J Hughes1, C Colosimo, B Kleedorfer, S E Daniel, A J Lees.   

Abstract

Fifteen of 23 pathologically confirmed cases of multiple system atrophy (MSA) showed some initial response to levodopa and eight of these remained at least partially responsive at the time of death. Eleven developed motor oscillations, and drug-induced dyskinesias, often involving the face and jaw, were also seen in 11 cases. Acute levodopa and apomorphine challenges were administered to 11 patients with clinical MSA who were considered levodopa responsive. A short duration relatively small amplitude response with associated dyskinesias occurred in six and a further three developed dyskinesias without any motor response. Following levodopa withdrawal, a delayed deterioration occurred after three to six days in six patients, five of whom had shown no short duration motor response to the acute challenges. The occurrence of levodopa-induced dyskinesias without a concomitant motor response and delayed deterioration several days after levodopa withdrawal may be more typical of patients with MSA than Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469394      PMCID: PMC1015283          DOI: 10.1136/jnnp.55.11.1009

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  Research diagnostic criteria for Parkinson's disease.

Authors:  C D Ward; W R Gibb
Journal:  Adv Neurol       Date:  1990

2.  [Striato-nigral degeneration. Apropos of a clinical, therapeutic, and anatomic study of 2 cases].

Authors:  G Boudin; A Guillard; J Mikol; P Galle
Journal:  Rev Neurol (Paris)       Date:  1976-02       Impact factor: 2.607

3.  Alternate day levodopa therapy in parkinsonism.

Authors:  W C Koller
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

4.  [Striato-nigral degeneration. Clinical and anatomic study of a case which responded favorably to L-Dopa].

Authors:  J R Feve; J M Mussini; J F Mathé; J M Cler; M F Nomballais
Journal:  Rev Neurol (Paris)       Date:  1977-04       Impact factor: 2.607

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

7.  Levodopa efficacy and pathological basis of Parkinson syndrome.

Authors:  A H Rajput; B Rozdilsky; A Rajput; L Ang
Journal:  Clin Neuropharmacol       Date:  1990-12       Impact factor: 1.592

8.  Striatonigral degeneration. A clinicopathological study.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1990-12       Impact factor: 13.501

9.  Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation.

Authors:  R W Murrow; G D Schweiger; J J Kepes; W C Koller
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

Review 10.  Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

View more
  35 in total

Review 1.  Multiple system atrophy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

2.  Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

Authors:  C Alves Do Rego; I J Namer; C Marcel; F Lefebvre; O Lagha-Boukbiza; M Renaud; C Tranchant; M Anheim
Journal:  J Neurol       Date:  2018-06-28       Impact factor: 4.849

Review 3.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 4.  Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology.

Authors:  S Gilman; P Low; N Quinn; A Albanese; Y Ben-Shlomo; C Fowler; H Kaufmann; T Klockgether; A Lang; P Lantos; I Litvan; C Mathias; E Oliver; D Robertson; I Schatz; G Wenning
Journal:  Clin Auton Res       Date:  1998-12       Impact factor: 4.435

5.  Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.

Authors:  C Colosimo; M Merello; F E Pontieri
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

6.  Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.

Authors:  Randel L Swanson; Andrew B Newberg; Paul D Acton; Andrew Siderowf; Nancy Wintering; Abass Alavi; P David Mozley; Karl Plossl; Michelle Udeshi; Howard Hurtig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

7.  Clinicopathological study of 35 cases of multiple system atrophy.

Authors:  G K Wenning; Y Ben-Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 9.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Diagnosis of multiple system atrophy.

Authors:  Jose-Alberto Palma; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Auton Neurosci       Date:  2017-10-23       Impact factor: 3.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.